Clinical Trials Browser

Phase 3 × INDUSTRY × Lymphoproliferative Disorders × Clear all

Lymphoproliferative Disorders, Epstein-Barr Virus Infections

NCT02393859 2024-05-29

Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)

Phase 3 Completed

111 enrolled 23 charts 1 FDA

LymphoidOther hematologic neoplasm

Immunoproliferative Disorders, Lymphoproliferative Disorders, Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05431179 2023-04-21

A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma

Phase 3 Withdrawn

Lymphoid

Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Lymphoma, B-Cell, Lymphoma, Mantle-Cell

NCT01420679 2021-11-19

Pralatrexate vs Observation Following CHOP-based Chemotherapy in Undiagnosed Peripheral T-cell Lymphoma Patients

Phase 3 Terminated

21 enrolled 8 charts

Lymphoid

Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral

NCT00773747 2021-04-30

Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN)

Phase 3 Completed

637 enrolled 15 charts

LymphoidPlasma cell

Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, Hemorrhagic Disorders, Immune System Diseases, Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Vascular Diseases, Hemostatic Disorders, Neoplasms, Plasma Cell

NCT01650805 2014-11-17

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Phase 3 Terminated

307 enrolled 11 charts

LymphoidMyeloidOther hematologic neoplasm

Bone Marrow Diseases, Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Leukemia, Myeloid, Lymphatic Diseases, Lymphoproliferative Disorders, Myeloproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01101399 2013-12-18

FID-CHEMO

Phase 3 Completed

19 enrolled

Classical hematologyLymphoid

Anemia, Lymphoproliferative Disorders, Anemia, Iron-Deficiency

Clinical Trials

ALLELE

Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)

A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma

Pralatrexate vs Observation Following CHOP-based Chemotherapy in Undiagnosed Peripheral T-cell Lymphoma Patients

Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN)

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

FID-CHEMO